|
|
||||||||
J. Biol. Chem., Vol. 281, Issue 40, 30132-30142, October 6, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




¶1
From the
Departments of
Medicine, Digestive Health Center of Excellence, and ¶Microbiology, University of Virginia Health System, Charlottesville, Virginia 22908, and the
Department of Chemistry, University of North Carolina at Charlotte, Charlotte, North Carolina 28223
The Toll/Interleukin-1 receptor (TIR) domain of the Toll-like receptors (TLRs) plays an important role in innate host defense signaling. The TIR-TIR platform formed by the dimerization of two TLRs promotes homotypic protein-protein interactions with additional cytoplasmic adapter molecules to form an active signaling complex resulting in the expression of pro- and anti-inflammatory cytokine genes. To generate a better understanding of the functional domains of TLR2 we performed a random mutagenesis analysis of the human TLR2 TIR domain and screened for TLR2/1 signaling-deficient mutants. Based upon the random mutagenesis results, we performed an alanine scanning mutagenesis of the TLR2 DD loop and part of the
D region. This resulted in the identification of four residues crucial for TLR2/1 signaling: Arg-748, Phe-749, Leu-752, and Arg-753. Computer-assisted energy minimization and docking studies indicated three regions of interaction in the TLR2/1 TIR-docked heterodimer. In Region I, residues Arg-748 and Phe-749 in TLR2 DD loop were involved in close contacts with Gly-676 in the TLR1 BB loop. Because this model suggested that steric hindrance would significantly alter the binding interactions between DD loop of TLR2 and BB loop of TLR1, Gly-676 in TLR1 was rationally mutated to Ala and Leu. As expected, in vitro functional studies involving TLR1 G676A and TLR1 G676L resulted in reduced PAM3CSK4 mediated NF-
B activation lending support to the computerized predictions. Additionally, mutation of an amino acid residue (TLR2 Asp-730) in Region II also resulted in decreased activity in agreement with our model, providing new insights into the structure-function relationship of TLR2/1 TIR domains.
Received for publication, March 3, 2006 , and in revised form, June 22, 2006.
* This work was supported by grants from the National Institutes of Health (R01-AI34358), the American Heart Association (to M. F. S.), and the Immunology/Cell Isolation Core of the UVA Silvio O. Conte Digestive Health Research Center (DK 56703). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom correspondence should be addressed: University of Virginia Health System, PO Box 800708, Charlottesville, VA 22908-0708. Tel.: 434-924-2573; Fax: 434-243-9645; E-mail: mfs3k{at}virginia.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
T. Nyman, P. Stenmark, S. Flodin, I. Johansson, M. Hammarstrom, and P. Nordlund The Crystal Structure of the Human Toll-like Receptor 10 Cytoplasmic Domain Reveals a Putative Signaling Dimer J. Biol. Chem., May 2, 2008; 283(18): 11861 - 11865. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Keestra, M. R. de Zoete, R. A. M. H. van Aubel, and J. P. M. van Putten The Central Leucine-Rich Repeat Region of Chicken TLR16 Dictates Unique Ligand Specificity and Species-Specific Interaction with TLR2 J. Immunol., June 1, 2007; 178(11): 7110 - 7119. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Y. Toshchakov, M. J. Fenton, and S. N. Vogel Cutting Edge: Differential Inhibition of TLR Signaling Pathways by Cell-Permeable Peptides Representing BB Loops of TLRs J. Immunol., March 1, 2007; 178(5): 2655 - 2660. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |